Table 2.
Outcomes by Lipid‐Lowering Treatment Group
| Usual Care | Pravastatin | HR (95% CI) | P Value | |
|---|---|---|---|---|
| 10‐y Rate per 100 Persons (SE) | 10‐y Rate per 100 Persons (SE) | |||
| Mortality outcomes | ||||
| Total analyzed | 5110 | 5089 | 10199 | |
| All‐cause mortality | 31.0 (0.7) | 30.1 (0.7) | 0.96 (0.89–1.03) | .24 |
| CV mortality | 15.1 (0.6) | 14.2 (0.5) | 0.93 (0.84–1.04) | .19 |
| CHD | 7.9 (0.4) | 7.0 (0.4) | 0.89 (0.76–1.03) | .11 a |
| Black | 8.6 (0.7) | 6.7 (0.6) | 0.74 (0.58–0.94) | .01 |
| Non‐black | 7.4 (0.5) | 7.2 (0.5) | 1.00 (0.83–1.21) | 1.00 |
| Stroke | 2.4 (0.2) | 2.4 (0.2) | 1.02 (0.78–1.33) | .89 b |
| Black | 2.2 (0.4) | 2.8 (0.4) | 1.33 (0.87–2.04) | .19 |
| Non‐black | 2.4 (0.3) | 2.0 (0.3) | 0.85 (0.60–1.21) | .37 |
| Heart failure | 1.6 (0.2) | 1.6 (0.2) | 0.95 (0.69–1.31) | .74 |
| Other CVD | 4.1 (0.3) | 4.0 (0.3) | 0.97 (0.79–1.19) | .76 |
| Non‐CV mortality | 17.7 (0.6) | 17.5 (0.6) | 0.98 (0.89–1.08) | .71 |
| Cancer | 7.5 (0.4) | 8.0 (0.4) | 1.04 (0.90–1.20) | .62 |
| Kidney disease | 0.9 (0.2) | 1.0 (0.2) | 1.10 (0.72–1.69) | .66 c |
| Black | 0.9 (0.2) | 1.5 (0.3) | 1.40 (0.76–2.60) | .28 |
| Non‐black | 1.0 (0.2) | 0.7 (0.2) | 0.85 (0.46–1.56) | .60 |
| Accident, suicide, homicide | 0.8 (0.1) | 0.7 (0.1) | 0.83 (0.51–1.35) | .46 |
| Other non‐CVD | 9.4 (0.5) | 8.7 (0.4) | 0.94 (0.81–1.07) | .34 |
| Unknown cause | 1.2 (0.2) | 1.3 (0.2) | 0.97 (0.66–1.41) | .86 |
| Combined fatal or nonfatal hospitalized events | ||||
| Total analyzed | 3325 | 3313 | 6638 | |
| CHD | 17.5 (0.8) | 15.9 (0.7) | 0.92 (0.81–1.04) | .19 d |
| Black | 16.7 (1.2) | 14.2 (1.1) | 0.79 (0.64–0.98) | .032 |
| Non‐black | 17.9 (1.0) | 17.0 (1.0) | 1.01 (0.86–1.18) | .95 |
| CVD | 36.1 (1.0) | 34.8 (1.0) | 0.95 (0.87–1.04) | .28 |
| Heart failure | 13.8 (0.7) | 14.0 (0.7) | 0.99 (0.85–1.14) | .86 |
| Stroke | 12.9 (0.7) | 11.7 (0.7) | 0.90 (0.77–1.05) | .18 e |
| Black | 13.6 (1.2) | 12.8 (1.1) | 0.99 (0.78–1.26) | .95 |
| Non‐black | 12.6 (0.9) | 10.9 (0.8) | 0.84 (0.69–1.03) | .09 |
| GI bleed | 21.1 (0.9) | 20.6 (0.9) | 0.99 (0.88–1.12) | .92 |
| ESRD from USRDS | ||||
| Total analyzed | 5110 | 5089 | 10199 | |
| ESRD | 2.4 (0.2) | 2.6 (0.3) | 1.09 (0.83–1.41) | .54 f |
| Black | 3.0 (0.4) | 4.6 (0.6) | 1.36 (0.96–1.94) | .085 |
| Non‐black | 2.0 (0.3) | 1.3 (0.2) | 0.77 (0.51–1.17) | .22 |
Abbreviations: CHD, coronary heart disease; CI, confidence interval; CV, cardiovascular; CVD, cardiovascular disease; ESRD, end‐stage renal disease; GI, gastrointestinal; HR, hazard ratio; SD, standard deviation; SE, standard error; USRDS, US Renal Data System; VA, Veterans Administration. aCHD mortality treatment × race interaction, P=.052. bStroke mortality treatment × race interaction, P=.11. cKidney disease mortality treatment × race interaction, P=.26. dCombined fatal and nonfatal CHD events treatment × race interaction, P=.08. eCombined fatal and nonfatal stroke events treatment × race interaction, P=.30. fUSRDS ESRD events treatment × race interaction, P=.041.